2004
DOI: 10.1038/sj.mp.4001494
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Genetic factors contribute to the phenotype of drug response. We systematically analyzed all available pharmacogenetic data from Medline databases on the impact that genetic polymorphisms have on positive and adverse reactions to antidepressants and antipsychotics. Additionally, dose adjustments that would compensate for genetically caused differences in blood concentrations were calculated. To study pharmacokinetic effects, data for 36 antidepressants were screened. We found that for 20 of those, data on pol… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

9
414
0
20

Year Published

2006
2006
2020
2020

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 637 publications
(443 citation statements)
references
References 305 publications
9
414
0
20
Order By: Relevance
“…Another partial meta-analysis has been reported but in the context of a wider review and including only a small part of the studies here included and with a large heterogeneity of treatments. 47 In conclusion, our meta-analysis confirmed the significant association of the l variant of 5-HTTLPR with a better response to SSRIs and this effect seemed independent from ethnic differences. The subjects with s/s genotype have difficulties to reach remission, Figure 6 Outcome data for l/l versus l/s and s/s in remission rate, response rate and response rate within 4 weeks in Asian subjects.…”
Section: -Httlpr and Ssri Meta-analysissupporting
confidence: 72%
“…Another partial meta-analysis has been reported but in the context of a wider review and including only a small part of the studies here included and with a large heterogeneity of treatments. 47 In conclusion, our meta-analysis confirmed the significant association of the l variant of 5-HTTLPR with a better response to SSRIs and this effect seemed independent from ethnic differences. The subjects with s/s genotype have difficulties to reach remission, Figure 6 Outcome data for l/l versus l/s and s/s in remission rate, response rate and response rate within 4 weeks in Asian subjects.…”
Section: -Httlpr and Ssri Meta-analysissupporting
confidence: 72%
“…In our study comprising 181 patients, we demonstrated that CYP2D6 poor metabolizers (SGD = 0) should receive 40% of the dose for an extensive metabolizer with SGD = 2. This corresponds well to the IMI dose adjustment previously suggested 52 (28 of 131% is 37% for a poor metabolizer dose compared to an extensive metabolizer). For intermediate metabolizers, for which the combined SGDs of 0.5 and 1 result in an average dose of 63% in our study, this is lower than the extrapolated 103% (79 of 131%) based on Kirchheiner et al 52 Obviously, the precise benefit of pharmacogenetic individualisation will have to be supported by future prospective studies of pretherapeutic genotyping, before exact dose recommendations can subsequently be validated.…”
Section: Discussionsupporting
confidence: 87%
“…This corresponds well to the IMI dose adjustment previously suggested 52 (28 of 131% is 37% for a poor metabolizer dose compared to an extensive metabolizer). For intermediate metabolizers, for which the combined SGDs of 0.5 and 1 result in an average dose of 63% in our study, this is lower than the extrapolated 103% (79 of 131%) based on Kirchheiner et al 52 Obviously, the precise benefit of pharmacogenetic individualisation will have to be supported by future prospective studies of pretherapeutic genotyping, before exact dose recommendations can subsequently be validated. Comparable studies with the second-generation selective serotonin reuptake inhibitor antidepressants metabolized by CYP2D6 (such as paroxetine and venlafaxine) 27 will also be of interest.…”
Section: Discussionsupporting
confidence: 87%
“…1,2 For example, emerging data suggest that polymorphisms in central nervous system genes predict therapeutic response to antipsychotics, 3 antidepressants, 4 stimulant medications 5 and pharmacotherapy for dependence on alcohol 6 and tobacco. 7 Genetic tests can also identify patients most likely to suffer adverse side effects of treatment, such as tardive dyskinesia 8 and weight gain.…”
Section: Introductionmentioning
confidence: 99%
“…7 Estimates of pharmacogenetic effects in these trials are within the range of those observed for a variety of psychiatric medications. 2 Therefore, this analysis may be considered as a case study with applicability to the broader field of pharmacogenetics in psychiatry.…”
Section: Introductionmentioning
confidence: 99%